[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602743":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":11,"centralContacts":22,"locations":28,"responsibleParty":47,"collaborators":50,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":11,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":11,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":11,"overallStatus":31,"whyStopped":11,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"First Affiliated Hospital of Wannan Medical College","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":11},"standard treatment group","NO_INTERVENTION",null,{"label":13,"type":6,"description":11,"interventionNames":14},"standard treatment plus hemoadsorption group",[15],"Procedure: Hemoadsorption",[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":11},"PROCEDURE","Hemoadsorption","Patients in intervention group will receive standard treatment plus hemoadsorption therapy administered once on days 1, 3, and 5 following enrollment.",[13],[23],{"name":24,"role":25,"phone":26,"phoneExt":11,"email":27},"Fanfu Jin, Master","CONTACT","+86 18356201996","18356201996@sina.cn",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":11,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital)","RECRUITING","Wuhu","Anhui","China","CN",{"type":37,"coordinates":38},"Point",[39,40],118.42947,31.35259,{"lat":40,"lon":39},[43,44],{"name":24,"role":25,"phone":26,"phoneExt":11,"email":27},{"name":45,"role":46,"phone":11,"phoneExt":11,"email":11},"Shoucai Zhao, Doctor","PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Jie Xu","Director",[51,53,55,58,60,62,64,66,68],{"name":52,"class":6},"Anqing Municipal Hospital",{"name":54,"class":6},"Beijing Tiantan Hospital",{"name":56,"class":57},"Gansu Provincial Central Hospital","UNKNOWN",{"name":59,"class":6},"Baotou Central Hospital",{"name":61,"class":57},"The NO.1 People's Hospital of Shizuishan",{"name":63,"class":6},"Fuyang people's hospital",{"name":65,"class":6},"Second People's Hospital of Hefei City",{"name":67,"class":6},"The First Affiliated Hospital of Zhengzhou University",{"name":69,"class":57},"THE SECOND PEOPLE'S HOSPITAL, WUHU","100602743","hemoadsorption-for-severe-ischemic-stroke-100602743",false,"NCT07127484","Hemoadsorption for Severe Ischemic Stroke","Efficacy and Safety of Hemoadsorption for Severe Ischemic Stroke","Inclusion Criteria:\n\n1.18 years ≤ age \\\u003C 80 years; 2.Pre-stroke mRS score ≤ 1; 3.Anterior circulation cerebral infarction within 48 hours of onset, meeting at least one of the following:\n\n1. 15≤ NIHSS score ≤32;\n2. 3\\\u003CGCS score ≤12;\n3. CT hypodensity area \\>1\u002F2 of the MCA territory; 4.hs-CRP ≥2 mg\u002FL at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained.\n\nExclusion Criteria:\n\n1. Hemorrhagic transformation of PH2 type prior to randomization;\n2. Brain herniation or decompressive craniectomy performed before randomization;\n3. Hemodynamic instability refractory to medical correction (systolic blood pressure \\\u003C70 mmHg or diastolic blood pressure \\\u003C50 mmHg) or decompensated heart failure (NYHA Class III or IV);\n4. Severe hepatic impairment (defined as ALT \\>2 times the upper limit of normal or AST \\>2 times the upper limit of normal) and renal impairment (defined as serum creatinine \\>1.5 times the upper limit of normal or estimated glomerular filtration rate \\[eGFR\\] \\\u003C50 mL\u002Fmin);\n5. Coagulopathy or thrombocytopenia (platelet count \\\u003C100×10⁹\u002FL);\n6. Deep vein thrombosis (DVT) of the lower extremities before randomization;\n7. Life expectancy \\\u003C90 days due to malignancy;\n8. Participation in another drug or device clinical trial within the past 30 days or ongoing enrollment in such trials;\n9. Women of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or pregnant\u002Flactating women;\n10. Absolute contraindications to hemoadsorption therapy.","ALL","18 Years","80 Years",{"count":81,"type":82},116,"ESTIMATED","INTERVENTIONAL",[85],"NA","This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke",[88,19],"Ischemic Stroke","2026-05-13",{"date":91,"type":92},"2026-05-15","ACTUAL",{"date":94,"type":92},"2026-01-05",{"date":96,"type":82},"2027-02-28",{"name":5,"class":6},1]